DK1545710T3 - Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer - Google Patents

Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer

Info

Publication number
DK1545710T3
DK1545710T3 DK03792501T DK03792501T DK1545710T3 DK 1545710 T3 DK1545710 T3 DK 1545710T3 DK 03792501 T DK03792501 T DK 03792501T DK 03792501 T DK03792501 T DK 03792501T DK 1545710 T3 DK1545710 T3 DK 1545710T3
Authority
DK
Denmark
Prior art keywords
methylpyrazin
oxadiazol
sulfonamide
pyridine
methoxy
Prior art date
Application number
DK03792501T
Other languages
Danish (da)
English (en)
Inventor
David William Tonge
Sian Tomiko Taylor
Francis Thomas Boyle
Andrew Mark Hughes
Donna Johnstone
Marianne Bernice Ashford
Nigel Charles Barrass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1545710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1545710T3 publication Critical patent/DK1545710T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03792501T 2002-08-23 2003-08-20 Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer DK1545710T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use
PCT/GB2003/003653 WO2004018044A2 (en) 2002-08-23 2003-08-20 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent

Publications (1)

Publication Number Publication Date
DK1545710T3 true DK1545710T3 (da) 2009-06-29

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792501T DK1545710T3 (da) 2002-08-23 2003-08-20 Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer

Country Status (32)

Country Link
US (2) US7820679B2 (xx)
EP (2) EP2072082A3 (xx)
JP (2) JP3663202B2 (xx)
KR (1) KR20050035280A (xx)
CN (1) CN100467023C (xx)
AR (1) AR041037A1 (xx)
AT (1) ATE427773T1 (xx)
AU (1) AU2003255835B8 (xx)
BR (1) BR0313655A (xx)
CA (1) CA2496476C (xx)
CL (1) CL2003001692A1 (xx)
CY (1) CY1110712T1 (xx)
DE (1) DE60327084D1 (xx)
DK (1) DK1545710T3 (xx)
ES (1) ES2323309T3 (xx)
GB (1) GB0219660D0 (xx)
HK (1) HK1077534A1 (xx)
IL (1) IL166730A0 (xx)
IS (1) IS2704B (xx)
MX (1) MXPA05001862A (xx)
MY (2) MY136449A (xx)
NO (1) NO330756B1 (xx)
NZ (1) NZ538114A (xx)
PL (1) PL375561A1 (xx)
PT (1) PT1545710E (xx)
RU (1) RU2340343C2 (xx)
SA (1) SA03240363B1 (xx)
SI (1) SI1545710T1 (xx)
TW (1) TWI302912B (xx)
UA (1) UA82071C2 (xx)
WO (1) WO2004018044A2 (xx)
ZA (1) ZA200501267B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (ja) * 2006-03-28 2007-10-04 Osaka Bioscience Institute 血管新生ならびに癌細胞のmesenchymal型およびamoeboid型浸潤を阻害するための薬剤
WO2009024820A2 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Therapeutic treatment 014
DK2209501T3 (da) 2007-10-12 2012-02-27 Astrazeneca Ab Zibotentan-sammensætning, der indeholder mannitol og mikrokrystallinsk cellulose
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2010004337A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
BR112013029163A2 (pt) * 2011-05-17 2017-01-31 Plexxikon Inc modulação quinase e indicações dos mesmos
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
KR101855382B1 (ko) * 2015-12-31 2018-05-04 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (xx) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (xx) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
JP2003520785A (ja) * 1999-12-15 2003-07-08 ブリストル−マイヤーズ スクイブ カンパニー アンジオテンシン・エンドセリン受容体二重拮抗薬としてのビフェニルスルホンアミド類
ES2277856T3 (es) 2000-02-16 2007-08-01 Astellas Pharma Inc. Remedios para enfermedades inducidas por endotelina.
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
CA2440141A1 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
JP2005503339A (ja) 2001-04-11 2005-02-03 アボット・ラボラトリーズ 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
AU2002355266A1 (en) 2001-07-23 2003-02-17 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
ATE498408T1 (de) 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
ATE507220T1 (de) 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
MXPA05001862A (es) 2005-06-03
NZ538114A (en) 2008-02-29
WO2004018044A2 (en) 2004-03-04
US20060094729A1 (en) 2006-05-04
NO20050689L (no) 2005-03-21
JP2004083590A (ja) 2004-03-18
AU2003255835A1 (en) 2004-03-11
JP3663202B2 (ja) 2005-06-22
CL2003001692A1 (es) 2005-01-21
PL375561A1 (en) 2005-11-28
TW200409768A (en) 2004-06-16
MY136449A (en) 2008-10-31
SI1545710T1 (sl) 2009-08-31
ZA200501267B (en) 2006-10-25
EP1545710A2 (en) 2005-06-29
ATE427773T1 (de) 2009-04-15
KR20050035280A (ko) 2005-04-15
RU2340343C2 (ru) 2008-12-10
SA03240363B1 (ar) 2009-04-11
IS2704B (is) 2010-12-15
US20110003831A1 (en) 2011-01-06
CN100467023C (zh) 2009-03-11
CY1110712T1 (el) 2015-06-10
AR041037A1 (es) 2005-04-27
UA82071C2 (xx) 2008-03-11
EP2072082A2 (en) 2009-06-24
DE60327084D1 (de) 2009-05-20
IL166730A0 (en) 2006-01-15
GB0219660D0 (en) 2002-10-02
WO2004018044A3 (en) 2004-05-06
CN1688365A (zh) 2005-10-26
PT1545710E (pt) 2009-05-26
TWI302912B (en) 2008-11-11
NO330756B1 (no) 2011-07-04
MY137595A (en) 2009-02-27
EP2072082A3 (en) 2009-12-23
AU2003255835B8 (en) 2007-05-17
WO2004018044A8 (en) 2004-06-24
AU2003255835B2 (en) 2007-04-05
EP1545710B1 (en) 2009-04-08
BR0313655A (pt) 2005-06-21
US7820679B2 (en) 2010-10-26
HK1077534A1 (en) 2006-02-17
ES2323309T3 (es) 2009-07-13
CA2496476C (en) 2009-08-04
IS7766A (is) 2005-03-22
CA2496476A1 (en) 2004-03-04
RU2005108349A (ru) 2005-08-27
JP2005097312A (ja) 2005-04-14

Similar Documents

Publication Publication Date Title
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DK1480615T3 (da) Superfin formoterolformulering
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
PT102750B (pt) Geladeira portatil aperfeicoada
DK1663236T3 (da) Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat
CY2013031I2 (el) Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
DE60232547D1 (de) Kosmetika
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
DE60234388D1 (de) Therapeutische lotion gegen dermatitis
ATE399523T1 (de) Haarbehandlungszusammensetzung
ZA200704104B (en) A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
ATE326208T1 (de) Haarbehandlungszusammensetzungen
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
ATE515382T1 (de) Holzbehandlungsformulierung
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
ITMO20020368A1 (it) Mezzi di finitura perfezionati.
ES1051471Y (es) Sandalia multiforme perfeccionada
ITPG20020067A1 (it) Dermo terapia
ES1051158Y (es) Monedero perfeccionado
ES1051442Y (es) Monedero perfeccionado.
ES1050962Y (es) Monedero perfeccionado.